National Cancer Institute (NCI)
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.
PRIMARY OBJECTIVE: I. To identify the safety and maximally tolerated dose (MTD) of oral triapine used in combination with radiation therapy for patients with recurrent glioblastoma (GBM) or astrocytoma. SECONDARY OBJECTIVES: I. To observe and record anti-tumor activity. II. To determine the pharmacokinetics of oral triapine in plasma and the central nervous system (CNS). III. To evaluate the efficacy of triapine when administered in combination with radiation therapy by assessing: IIIa. Progression-free survival (PFS); IIIb. Overall survival (OS); IIIc. The proportion of patients requirin…
Inclusion Criteria: * Patients must have histologically, molecularly, or cytologically confirmed recurrent astrocytic tumors including: * GBM or variants, IDH-wildtype, grade 2-4 (standard curative measures available or not) * Astrocytoma, IDH-mutant, grade 2-4 (standard curative measures available or not) * Diffuse midline gliomas, including pediatric-type H3 G34 or E3 K27 mutant tumors. * Tumors ≤ 6 cm in maximal diameter. * Patients who had recent resection for recurrent tumor must have measurable disease. * Patients must have at least a 6-month break from last dose of radiation…
Undergo blood and CSF sample collection
Undergo CT
Undergo IMRT
Undergo MRI
Given PO